Can Weight-Loss drugs outperform diet and exercise for heart health?

NCT ID NCT07740291

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study compares two weight-loss strategies: GLP-1 medications (like semaglutide or tirzepatide) versus a structured diet and exercise program. Adults with a BMI of 27.5 or higher are followed for three months to see which approach better improves heart and metabolic markers, such as blood sugar, cholesterol, and blood pressure. The trial also looks at changes in appetite hormones, gene activity, and mental well-being, including eating behaviors and stress. The goal is to understand the broader health impacts of each method beyond just weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonist medications (semaglutide or tirzepatide) compared with a structured lifestyle intervention (reduced-calorie diet and increased physical activity)
What this could lead to
If successful, this could clarify which weight-loss approach—medication or lifestyle—better improves heart and metabolic health, and may guide personalized treatment choices for obesity.
What could go wrong
This is a small pilot study, so results may not be conclusive or generalizable. The medication group is not randomized, and dosing is determined by each participant's own doctor, which could introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADDICTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior, Addictive eating disorder Feeding and Eating Disorders mental disorder Obesity obesity disorder Overweight Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nutrition Metabolic Health Initiative (NMHI)

    RECRUITING

    Lubbock, Texas, 79410, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.